<code id='00ACFE5790'></code><style id='00ACFE5790'></style>
    • <acronym id='00ACFE5790'></acronym>
      <center id='00ACFE5790'><center id='00ACFE5790'><tfoot id='00ACFE5790'></tfoot></center><abbr id='00ACFE5790'><dir id='00ACFE5790'><tfoot id='00ACFE5790'></tfoot><noframes id='00ACFE5790'>

    • <optgroup id='00ACFE5790'><strike id='00ACFE5790'><sup id='00ACFE5790'></sup></strike><code id='00ACFE5790'></code></optgroup>
        1. <b id='00ACFE5790'><label id='00ACFE5790'><select id='00ACFE5790'><dt id='00ACFE5790'><span id='00ACFE5790'></span></dt></select></label></b><u id='00ACFE5790'></u>
          <i id='00ACFE5790'><strike id='00ACFE5790'><tt id='00ACFE5790'><pre id='00ACFE5790'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:comprehensive    Page View:16
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In